<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="219291">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00229476</url>
  </required_header>
  <id_info>
    <org_study_id>03-08-033</org_study_id>
    <secondary_id>H6U-US-X002</secondary_id>
    <secondary_id>04012549</secondary_id>
    <nct_id>NCT00229476</nct_id>
  </id_info>
  <brief_title>Study of Medication and Placebo Response in Major Depression</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <brief_summary>
    <textblock>
      The primary purpose of the research study is to use recordings of brain electrical activity
      (through electroencephalogram, or EEG) and symptom measurements to determine whether
      patients are likely to show a response to medication or placebo treatment during a treatment
      trial for depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>depressive symptoms</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>brain electrical activity (EEG)</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline (Zoloft)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical Diagnosis of Unipolar Major Depression

        Exclusion Criteria:

          -  Substance Abuse, Psychotic Disorder, History of Severe Head Trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew F. Leuchter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Neuropsychiatric Institute &amp; Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002 Jan;159(1):122-9.</citation>
    <PMID>11772700</PMID>
  </reference>
  <reference>
    <citation>Cook IA, Leuchter AF, Morgan M, Witte E, Stubbeman WF, Abrams M, Rosenberg S, Uijtdehaage SH. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology. 2002 Jul;27(1):120-31.</citation>
    <PMID>12062912</PMID>
  </reference>
  <reference>
    <citation>Leuchter AF, Morgan M, Cook IA, Dunkin J, Abrams M, Witte E. Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression. Psychopharmacology (Berl). 2004 Dec;177(1-2):15-22. Epub 2004 Jul 14.</citation>
    <PMID>15252704</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 3, 2016</lastchanged_date>
  <firstreceived_date>September 28, 2005</firstreceived_date>
  <keyword>Depression</keyword>
  <keyword>EEG</keyword>
  <keyword>QEEG</keyword>
  <keyword>cordance</keyword>
  <keyword>Zoloft</keyword>
  <keyword>sertraline</keyword>
  <keyword>placebo</keyword>
  <keyword>electroencephalogram</keyword>
  <keyword>brain</keyword>
  <keyword>antidepressants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
